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Synthetic and crystallographic insight into exploiting sp2-
hybridization in the development of D-L-fucosidase inhibitors 
Travis Coyle,[a][b] Liang Wu,[c] Aleksandra W. Debowski,[a] Gideon J. Davies[c] and Keith A. Stubbs*[a] 
 
Abstract: The sugar fucose plays a myriad of roles in biological 
recognition. Enzymes hydrolyzing fucose from glycoconjugates, Į-L-
fucosidases, are important targets for inhibitor and probe 
development. Here we describe the synthesis and evaluation of 
novel Į-L-fucosidase inhibitors, with X-ray crystallographic analysis 
using an Į-L-fucosidase from Bacteroides thetaiotamicron helping to 
lay a foundation for future development of inhibitors for this 
important enzyme class. 
Many of the glycoconjugates that are found in eukaryotes bear 
terminal Į-L-fucose residues; these glycans facilitate a variety of 
biological functions including cell-cell interactions, adhesion, 
inflammation and antigen determination.[1] Reflecting the 
important roles of this carbohydrate motif, there are specific 
enzymes, termed Į-L-fucosidases (which are part of a larger 
class of enzymes termed glycoside hydrolases[2]), that act to 
cleave Į-L-fucose moieties from glycoconjugates. This 
enzymatic process mediates the distribution of fucosylated 
glycans, and dysfunction or abnormal distribution of Į-L-
fucosidases in humans is associated with several disease 
states.[3-5] 
As with other glycoside hydrolases, Į-L-fucosidases have 
been classified into families based upon amino acid sequence 
homologies, with known Į-L-fucosidases falling into GH families 
GH29 and GH95. Due to the importance of fucosidases and 
glycoside hydrolases in general, efforts have been made to 
understand the function of these enzymes focusing on substrate 
recognition and catalytic mechanism. This understanding has 
greatly benefited from the use of chemically synthesized small 
molecule inhibitors in concert with X-ray crystallography. 
Specifically for GH29 Į-L-fucosidases, these enzymes retain the 
configuration, relative to the substrate, at the anomeric carbon 
after hydrolysis with the catalytic mechanism being 
demonstrated to proceed through a double-displacement 
mechanism with a covalent ȕ-glycosyl-enzyme intermediate 
(Figure 1A).[6] Using X-ray crystallography, structures have been 
obtained of the glycosyl-enzyme intermediate[7] which have 
revealed a putative conformational itinerary for these enzymes 
of 1C4-
3H4-
3S1 with the putative oxocarbenium ion-like  
Figure 1. (A) GH29 fucosidases use a retaining catalytic mechanism involving 
a glycosyl-enzyme intermediate such that the overall reaction proceeds with 
net retention of stereochemistry. (B) Putative transition state for GH29 
fucosidases. (C) Structures of known inhibitors of GH29 Į-L-fucosidases. (D) 
Structure of the inhibitor PUGNAc and overall general structure of the 
corresponding inhibitors relevant to the described work described. 
transition state around the 3H4 conformation (Figure 1B). 
In regards to inhibition, different aspects of the putative 
transition state, namely charge and shape, have been exploited 
giving compounds that act as inhibitors. For example 
compounds that mimic the charge of the putative transition state 
such as amines 1[8] (and N-alkyl analogues[9]) and 2[8] have been 
shown to be potent inhibitors of Į-L-fucosidases (Figure 1C). 
Interestingly the ‘C1 epimer’ of 2 also displays good potency 
despite the molecule not adopting an Į-L-fucose structure.[8] The 
deoxy analogue 3[10] and pyrrolidine 4[11] are also good inhibitors 
of these enzymes and compounds prepared that mimic shape 
such as 5[12] and compounds such as 6,[13] developed by Vasella, 
which are though to mimic the charge and shape of the 
transition state also display good potency. 
In developing new types of inhibitors for GH29 Į-L-
fucosidases we were drawn to the inhibitor PUGNAc[14] (Figure 
1D) which has been shown to be a highly potent inhibitor of 
retaining E-N-acetylhexosaminidases.[15-19] PUGNAc’s potency is 
thought to lie in the compound possessing a transition state-like 
sp2-hybridised carbon at C1, rendering it a potent inhibitor for E-
N-acetylhexosminidase-catalysed reactions.[20, 21] In addition the 
oxime substituent is thought to provide additional binding energy 
by mimicking the aglycon of a natural substrate.[15] 
With these points in mind we felt, based on the putative 
conformational itinerary analysis that has been described for 
GH29 Į-L-fucosidases, that molecules bearing an sp2-hybridized 
anomeric carbon may act as inhibitors of these enzymes as they 
could potentially mimic the conformation of the putative 
transition state (Figure 1D). In addition the inhibitory potency of 
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these molecules could potentially be varied by modifying the 
oxime substituent, as has been demonstrated in the 
development of PUGNAc-based analogues.[22]  
Starting from L-fucose 7, peracetylation under standard 
conditions followed by selective deacetylation at the anomeric 
position gave the known hemiacetal 8 (Scheme 1).[23] Treatment 
of 8 with hydroxylamine hydrochloride and pyridine gave the 
presumed oximes 9 which were carried through without further 
purification. Treatment of 9 with DBU and NCS allowed for 
oxidative ring closure but upon purification both the desired 
oxime 10 and the 1,4-hydroximolactone isomer 11 were isolated. 
The formation of analogous side products to the undesired 
material 11 have been observed in the preparation of other 1,5-
hydroximolactones of this type.[24,25] Variation in temperature as 
well as the rate of addition of DBU did not improve the yield or 
selectivity for 10 but the yield was acceptable, so work continued 
on the functionalization of the hydroxyl motif. Before undertaking 
the preparation of various carbamates we first deprotected 10 
using sodium methoxide in methanol which provided the 1,5-
hydroximolactone 12. 
To access the panel of carbamates desired, we decided to 
utilize a method that has shown promise in the preparation of 
PUGNAc-based analogues where a suitable colourigenic 
carbonate is used as an intermediate as the formation of the 
desired carbamate can be indirectly monitored by observation of 
the liberated 4-nitrophenolate anion.[22] Thus, treatment of 10 
with 4-nitrophenyl chloroformate gave the presumed carbonate 
13. Treatment of this carbonate 13 with various anilines and 
amines led to the formation of the carbamates 14-28. The 
carbamates 14-28 were then deprotected to give the triols 29-43 
in good yield.  
Scheme 1. a) Ac2O, pyr.; b) EtNH2, AcOH, THF; c) NH2OH.HCl, pyr., MeOH; 
d) DBU, NCS, CH2Cl2; e) NaOMe, MeOH; f) 4-nitrophenyl chloroformate, 
DIPEA, THF; g) Amine or aniline-based compound, DIPEA; h) NH3, MeOH. 
Next, to gain insight into the inhibitory potency of 12 and 29-
43 against GH29 Į-L-fucosidases we evaluated them against the 
Į-L-fucosidase from bovine kidney (bFUCA1; one of the two Į-L-
fucosidases known to be expressed by Bos Taurus) using 4-
nitrophenyl Į-L-fucopyranoside as a substrate. All the 
compounds displayed activity as inhibitors against bFUCA1 
(Table 1). The 1,5-hydroximolactone 12 was a weak inhibitor 
(323 ± 12 PM) of the enzyme, which demonstrates the potential 
importance of the phenyl carbamoyl motif. This is in accordance 
with what has been observed for other inhibitors using this 
scaffold to target other enzyme classes[15,18] and also for other 
inhibitor scaffolds trying to mimic the transition state of GH29 Į-
L-fucosidase-mediated reactions.[26] Some trends were apparent 
in the relative activities of the carbamates. The N-alkyl chain 
carbamates 29-32 increased in potency with increasing chain 
length. This correlates with what has been observed for some 
carbasugar inhibitors of GH29 Į-L-fucosidases[9,27] and may 
indicate fortuitous hydrophobic binding interactions in or around 
the active site of the enzyme. Conversely, the activities of the 
other N-alkyl carbamates 33 and 34 decreased with increasing 
steric bulk close to the carbamoyl functional group. The relative 
activities of the cyclic alkyl carbamates 35-38 were in agreement 
with this observation; those with larger pendant rings were 
weaker inhibitors of the enzyme with this loss of activity most 
likely arising due to steric and electronic effects. Interestingly, 
significant increases in potency were observed for the N-aryl 
carbamates compared to the parent hydroximolactone 12.  
 
Table 1. Inhibition constants of prepared inhibitors against bovine kidney D-L-
fucosidase bFUCA1.  
 
Inhibitor R KI (PM) Inhibitor R KI (PM) 
29 (CH2)2CH3 190±11 37 CH(CH2)4 325±8 
30 CH2CHCH2 175±6 38 CH(CH2)5 580±7 
31 (CH2)3CH3 172±7 39 Ph 11±1 
32 (CH2)5CH3 143±8 40 p-BrPh 85±4 
33 CH(CH3)2 320±12 41 p-MeOPh 9.5±0.9 
34 C(CH3)3 440±9 42 4-CH3(CH2)3Ph 7.5±0.4 
35 CH(CH2)2 184±6 43 4-CH3(CH2)9Ph 4.8±0.5 
36 CH(CH2)3 220±12    
 
Comparison of 39 with the N-cyclohexyl carbamate 38 
demonstrates that given the similar shape, size, and 
hydrophobicity of the pendant moieties in these two inhibitors, 
the drastic increase in activity seems to be associated with the 
aromaticity of the pendant moiety. As such, it is likely that either 
specific interactions with the aromatic ring, such as S-stacking, 
or general hydrophobic effects and desolvation contribute to the 
strong activity of the inhibitors bearing pendant N-aryl 
carbamates. In addition, due to the increased potency of 41-43 
further evidence is provided for a putative hydrophobic binding 
pocket within the active site of bFUCA1, which may be exploited 
for the development of improved inhibitors.  
In the absence of a credible mammalian structural candidate, 
in order to gain a more detailed understanding of the molecular 
basis for the inhibition of GH29 Į-L-fucosidases, we obtained a 
1.7 Å crystal structure of 39 in complex with the D-L-fucosidase 
BT2970 from Bacteroides thetaiotamicron (See Supporting 
Table). BT2970 shares 27% identity with human FUCA1 and 
27% identity with bFUCA1, including near complete identity of 
active site residues (See Supporting Figure).  
After soaking crystals of BT2970 with 39 (KI of 39 against 
BT2970 equals 121 ± 24 PM), clear electron density 
corresponding to the ligand was observed in the active site of 
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BT2970 in crystallo (PDB code: 6HZY). As expected from the 
conformational itinerary, C3 lies “above” the ring plane with 39 
adopting a 3E conformation. In our experiments, BT2970 
crystallized in the I2 space group, with two molecules of protein 
in the asymmetric unit; both copies of BT2970 contained active 
site density for 39. Whilst electron density for the fucose portion 
of 39 was clear, the density grew progressively weaker along the 
‘aglycon’ portion of the ligand, likely reflecting increased 
molecular disorder as the ligand exits the enzyme active site. 
Although counter-intuitive, PUGNAc and related inhibitors with 
N-aryl carbamates are normally tighter-binding compounds than 
the parent hydroximolactones, but frequently the N-aryl group is  
Figure 2. a) ’Side’ view of 39 bound in the active site of BT2970, showing 
direct H-bonding interactions to nearby residues. The ligand shown is from 
chain B in the BT2970 crystal structure. Electron density is REFMAC 
maximum-likelihood/VA weighted 2FoíFc contoured to 0.29 electrons/Å3. b) 
Superposition of a bFUCA1 homology model (purple) against the ligand 
position from the BT2970-39 complex, showing Lys283, Lys285 and Phe286 
of the bFUCA1 homology model near the phenyl ring of 39. For clarity, 
electron density and BT2970 sidechains have been omitted from this image.  
disordered in crystal (as for example seen in VcNagZ[18,20]). The 
inhibitor 39 was observed to make similar H-bonding interactions 
within the BT2970 active site as previously observed for 
complexes with other fucose configured ligands[7], albeit the 
bulky ‘aglycon’ of 39 induced a degree of displacement of the 
catalytic acid/base residue Glu288, leading to disorder of the 
loop containing this residue. 
Due to the lack of interactions observed between BT2970 
and the phenyl ring of 39, it was not possible to analyze any 
enthalpic contributions of this moiety to binding in BT2970. In 
order to predict the possible interactions 39 might make with 
mammalian fucosidases, we generated a RaptorX homology 
model of the bovine D-L-fucosidase bFUCA1, templated upon 
the structure of a fucosidase from Thermatoga maritima 
(TM0306; PDB accession 2ZWY). 
Superposition of the BT2970-39 ligand complex with the 
bFUCA1 RaptorX model suggested that Lys283, Lys285 and 
Phe286 of bFUCA1 would reside in a loop near the projected 
phenyl moiety of bound 39, raising the possibility of cation-S or 
S-S interactions between bFUCA1 and the phenyl ring of 39, 
which are not present in BT2970 (Figure 2B). Lys285 and 
Phe286 are fully conserved between bovine and human FUCA1, 
and replaced by closely related Arg and Tyr residues in the 
closely related bovine and human FUCA2 enzymes (See 
Supporting Figure). The additional cation-S or S-S interactions 
available to mammalian GH29 enzymes may produce more 
potent inhibition for ligands with aromatic ‘aglycons’ compared to 
those with similarly sized aliphatic ‘aglycons’. 
In conclusion, we have developed new tools to study GH29 
Į-L-fucosidases. The phenyl carbamate 39 and the aryl 
derivatives 41-43 are potent inhibitors of GH29 Į-L-fucosidases, 
with the sp2-hybridized centre contributing to potency. The 
benefit of alkyl and aryl substituents does not simply reflect 
improved interactions, since - as observed in other systems - the 
aryl groups are disordered, but may also come from solvent 
reorganization upon binding. Collectively, the results obtained 
here suggest that inhibitors of this type, that mimic the shape of 
the ring at the transition state, have a place in the development 
of inhibitors of Į-L-fucosidases. 
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